Literature DB >> 19415278

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

Ulrike Bacher1, Susanne Schnittger, Wolfgang Kern, Tamara Weiss, Torsten Haferlach, Claudia Haferlach.   

Abstract

According to the new World Health Organization (WHO) classification (2008), chronic myeloid malignancies are divided in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and overlap MDS/MPN cases. From morphological aspects, these categories show overlaps. To evaluate whether these morphological similarities have genetic parallels, we investigated 1,851 cases with suspected/confirmed myelodysplastic or myeloproliferative diseases by chromosome banding and molecular analyses. Cytogenetics revealed aberrant karyotypes in 354 patients (19.1% of the original cohort) who were the basis of further analysis. The distribution of chromosomal aberrations differed significantly between categories. Isolated +9 and gain of 9p were exclusively observed in MPN (+9: 10/93; 11%; p < 0.001; +9p: 6/93; 7% of all aberrant MPN cases) but were not detected in MDS or MDS/MPN (p = 0.001). Isolated del(5q) (p = 0.002), -7 in combination with other aberrations (p = 0.016), and complex aberrations (p = 0.003) were 2.9- to 7.5-fold more frequent in MDS than in MPN. Trisomies 8 and 21 and del(20q) were comparably frequent in both subgroups. Interestingly, the MDS/MPN overlap cohort showed a higher frequency of -7 accompanied by other aberrations (3/17; 18% of all aberrant cases; p = 0.001), i(17)(q10) (2/17; 12%; p = 0.013), and +21 (2/17; 12%; p = 0.013) when compared to MPN or MDS only. These differences support the category for MDS/MPN within the new WHO classification. Overlaps between the diverse disorders were seen also for the JAK2V617F (MPN 66/89; 74%; MDS/MPN 4/14; 29%; MDS 2/63; 3%) and NRAS mutations (MDS 2/67; 3%; MPN 2/4; MDS/MPN 1/1). In conclusion, cytogenetics and molecular genetics show overlaps in varying proportions of MDS and MPN cases which might indicate common pathways in their etiology. Some markers are strongly associated with one of these disorders and can be helpful for differential diagnosis especially in difficult cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415278     DOI: 10.1007/s00277-009-0745-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

1.  Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.

Authors:  Ivo P Touw; Renée Beekman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

2.  Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.

Authors:  C Cameron Yin; Jie Peng; Yu Li; Rashmi Kanagal-Shamanna; Tariq Muzzafar; Courtney DiNardo; Joseph D Khoury; Shaoying Li; L Jeffrey Medeiros; Sa A Wang; Guilin Tang
Journal:  Mod Pathol       Date:  2015-06-05       Impact factor: 7.842

3.  MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

Authors:  A Stengel; W Kern; M Meggendorfer; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2017-06-08       Impact factor: 11.528

4.  Clinical utility gene card for: familial polycythaemia vera.

Authors:  Kais Hussein; Galit Granot; Ofer Shpilberg; Hans Kreipe
Journal:  Eur J Hum Genet       Date:  2012-10-03       Impact factor: 4.246

5.  Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.

Authors:  Ashley M Ramirez-Herrick; Shannon E Mullican; Andrea M Sheehan; Orla M Conneely
Journal:  Blood       Date:  2011-01-04       Impact factor: 22.113

Review 6.  Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 7.  Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.

Authors:  Pankaj Dwivedi; Kenneth D Greis
Journal:  Exp Hematol       Date:  2016-10-24       Impact factor: 3.084

Review 8.  An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.

Authors:  Chetasi Talati; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 9.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

10.  Complex and multifaceted therapy-related myeloid neoplasm following laryngeal cancer treated with Cisplatin and radiotherapy.

Authors:  Pasquale Niscola; Gianfranco Catalano; Andrea Tendas; Marco Giovannini; Laura Scaramucci; Benedetta Neri; Luciana Morino; Daniela Piccioni; Stefano Fratoni; Alessio Perrotti; Paolo de Fabritiis
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-15       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.